G Faa, M Piludu, M Piras, A Faa, R Sanfilippo, J S Suri, R Cau, L Saba
{"title":"The atherosclerotic plaque microenvironment: cellular plasticity, extracellular matrix remodeling, and plaque stability.","authors":"G Faa, M Piludu, M Piras, A Faa, R Sanfilippo, J S Suri, R Cau, L Saba","doi":"10.1016/j.vph.2026.107720","DOIUrl":"10.1016/j.vph.2026.107720","url":null,"abstract":"<p><p>The plaque microenvironment (PME) integrates systemic lipid exposure with local vascular, immune and stromal responses. Vascular smooth muscle cells, endothelial cells, monocytes, macrophages, fibroblast-like cells and lymphocytes interact within a continuously remodeled extracellular matrix. Their context-dependent states influence inflammation, lipid handling, matrix organization and the balance between plaque stability and vulnerability. This narrative review examines these cellular and extracellular components, with particular attention to phenotypic modulation, endothelial-to-mesenchymal transition and the limitations of inferring cellular origin from shared markers. Human single-cell findings expand the conventional M1/M2 view of macrophages. Therapeutic evidence is considered across experimental models, human pathology, intravascular imaging and randomized clinical outcome trials. Systemic lipid lowering and selected anti-inflammatory interventions can modify atherosclerotic disease, but changes in plaque composition do not by themselves establish reductions in myocardial infarction or stroke. Carotid and coronary findings also require site-specific interpretation. Integrating mechanistic observations with the level and anatomical setting of the evidence provides a framework for evaluating established therapies and developing selective PME-directed strategies.</p>","PeriodicalId":23949,"journal":{"name":"Vascular pharmacology","volume":" ","pages":"107720"},"PeriodicalIF":3.7,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149343695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jean Carlos Lipreri da Silva, Grace Whelan, Filipe de Farias F Martins, Tiago J Costa, Karla Bianca Neves
{"title":"A pathway-level analysis reveals oxidative and inflammatory vascular stress signatures associated with VEGF inhibition.","authors":"Jean Carlos Lipreri da Silva, Grace Whelan, Filipe de Farias F Martins, Tiago J Costa, Karla Bianca Neves","doi":"10.1016/j.vph.2026.107718","DOIUrl":"10.1016/j.vph.2026.107718","url":null,"abstract":"<p><p>Vascular endothelial growth factor inhibitors (VEGFi) are widely used in the treatment of advanced malignancies, including clear cell renal cell carcinoma (ccRCC), but are frequently associated with cardiovascular toxicities such as hypertension and endothelial dysfunction. The molecular mechanisms underlying these adverse effects remain incompletely understood. In this study, we performed an integrated transcriptomic and functional analysis to characterise vascular stress responses associated with VEGFi. Pre-treatment tumour RNA sequencing data from a public cancer cohort were analysed using Gene Set Enrichment Analysis (GSEA) to identify pathway-level signatures associated with subsequent VEGFi treatment. No individual genes remained significant after multiple testing correction; therefore, emphasis was placed on coordinated biological responses. Functional validation was conducted in human vascular cells treated with a VEGFi to assess reactive oxygen species (ROS) production, cytokine levels and expression, and extracellular vesicles (EVs) release. Pathway analysis revealed significant baseline enrichment of oxidative stress, inflammatory response, and nuclear factor-kappa B (NF-κB) signalling pathways in tumours of patients who subsequently received VEGFi. These baseline associations were complemented by increased vascular cell ROS production and enhanced EVs release in vitro. Inflammatory activation was further confirmed by increased cytokine secretion, despite unchanged messenger RNA expression, indicating regulation at post-transcriptional and secretory levels. Collectively, these baseline tumour signatures and the in vitro vascular findings are consistent with a model in which VEGF inhibition induces a coordinated redox-inflammatory response, which may involve EV-mediated intercellular communication. This mechanism may contribute to vascular dysfunction and cardiovascular toxicity associated with VEGFi-targeted therapies.</p>","PeriodicalId":23949,"journal":{"name":"Vascular pharmacology","volume":" ","pages":"107718"},"PeriodicalIF":3.7,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Suhong Lu, Nan Wang, Yingying Zhou, Ting Ran, Qingqing Deng, Hongyu Zhang, Xuekui Du, Xiaoxia Kong
{"title":"Fibroblast growth factor 10 (FGF10) ameliorates pulmonary arterial hypertension by restoring endothelial mitochondrial function and reducing DNA damage via the PPARγ pathway.","authors":"Suhong Lu, Nan Wang, Yingying Zhou, Ting Ran, Qingqing Deng, Hongyu Zhang, Xuekui Du, Xiaoxia Kong","doi":"10.1016/j.vph.2026.107714","DOIUrl":"10.1016/j.vph.2026.107714","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary arterial hypertension (PAH) is characterized by endothelial dysfunction, but the role of fibroblast growth factor 10 (FGF10) in regulating mitochondrial integrity and DNA damage remains unclear.</p><p><strong>Methods: </strong>A monocrotaline (MCT)-induced PAH rat model and MCTP-treated pulmonary artery endothelial cells were used. FGF10 was silenced using AAV- or lentivirus-mediated shRNA and supplemented exogenously. PPARγ involvement was assessed using GW9662 inhibition and Co-IP assays. Hemodynamic analysis, histology, and molecular assays were performed to evaluate vascular and endothelial alterations.</p><p><strong>Results: </strong>MCT exposure induced severe pulmonary vascular remodeling and endothelial mitochondrial injury, including fragmentation, reduced membrane potential, increased ROS, and persistent DNA damage responses. FGF10 knockdown aggravated these abnormalities, whereas exogenous FGF10 significantly restored mitochondrial structure and function, reduced oxidative stress, and attenuated DNA damage. Mechanistically, FGF10 upregulated PPARγ expression in vivo and in vitro. Pharmacological inhibition of PPARγ partially abolished the protective effects of FGF10. Co-IP further confirmed an interaction between FGF10 and PPARγ.</p><p><strong>Conclusion: </strong>FGF10 protects against MCT-induced pulmonary vascular remodeling by preserving mitochondrial homeostasis and limiting DNA damage in endothelial cells via a PPARγ-dependent mechanism. The FGF10-PPARγ axis may represent a potential therapeutic target for PAH, warranting further validation in additional models and translational studies.</p>","PeriodicalId":23949,"journal":{"name":"Vascular pharmacology","volume":" ","pages":"107714"},"PeriodicalIF":3.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149325162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Martino Pepe, Eduardo Urgesi, Rocco Tritto, Gianluigi Napoli, Salvatore Giordano, Angela Ivana Bruno, Pasquale Caldarola, Vincenzo Pestrichella, Paolo Colonna, Plinio Cirillo, Arturo Giordano, Giuseppe Biondi Zoccai, Sabino Iliceto, Marco Matteo Ciccone
{"title":"Ticagrelor pretreatment and angiographic no-reflow in STEMI: a multicentre observational study.","authors":"Martino Pepe, Eduardo Urgesi, Rocco Tritto, Gianluigi Napoli, Salvatore Giordano, Angela Ivana Bruno, Pasquale Caldarola, Vincenzo Pestrichella, Paolo Colonna, Plinio Cirillo, Arturo Giordano, Giuseppe Biondi Zoccai, Sabino Iliceto, Marco Matteo Ciccone","doi":"10.1016/j.vph.2026.107715","DOIUrl":"10.1016/j.vph.2026.107715","url":null,"abstract":"<p><strong>Aims: </strong>We examined the association between ticagrelor pretreatment and angiographic no-reflow in ST-segment elevation myocardial infarction (STEMI), with in-hospital mortality as a secondary outcome and clinical phenotyping as an exploratory objective.</p><p><strong>Methods: </strong>In a retrospective multicentre registry (2018-2021), 623 patients referred for percutaneous coronary intervention were compared by loading strategy: pretreatment at first medical contact or deferred before PCI. Cohort-wide inverse probability of treatment weighting (IPTW), using a clinical covariate-balancing propensity model and 50 imputations, estimated adjusted risk ratios (RRs). Outcome-blind latent class analysis preceded a treatment-weighted comparison of class-specific no-reflow risks.</p><p><strong>Results: </strong>No-reflow occurred in 28/464 pretreated patients versus 27/159 comparators (6.0% versus 17.0%); the crude RR was 0.36 (95% CI 0.22-0.58), and the IPTW-adjusted RR was 0.43 (95% CI 0.24-0.74; P = 0.003). Ten patients died (adjusted RR 0.46, 95% CI 0.13-1.67). Three classes comprised 328, 231 and 64 patients, but their pretreatment-standardised no-reflow risks did not establish prognostic separation.</p><p><strong>Conclusions: </strong>Ticagrelor pretreatment was associated with lower angiographic no-reflow after propensity weighting. The adjusted mortality and exploratory class-risk findings did not reach statistical significance. Residual confounding and uncertain covariate timing limit causal interpretation, and prospective validation is required.</p>","PeriodicalId":23949,"journal":{"name":"Vascular pharmacology","volume":" ","pages":"107715"},"PeriodicalIF":3.7,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Multi-omics and experimental validation reveal the proliferative mechanism of ACSL4 in pulmonary hypertension and identify potential FDA-approved drugs via in silico screening","authors":"Wei Chen, Yiting Dong, Qihao Shi, Hongbing Meng, Jiawei Sun, Congmei Han, Chenjie Yan, Chendong Wu, Jing Wang, Adriana Georgescu, Keke Jin, Linbo Yuan","doi":"10.1016/j.vph.2026.107694","DOIUrl":"10.1016/j.vph.2026.107694","url":null,"abstract":"<div><h3>Background</h3><div>Pulmonary hypertension (PH) is a life-threatening blood vessel disorder marked by remodeling of the pulmonary arteries. A key feature of this process is the uncontrolled growth of pulmonary artery smooth muscle cells (PASMCs). Although changes in fatty acid metabolism are thought to drive this abnormal cell growth, the exact molecular mechanisms behind it are still not fully understood.</div></div><div><h3>Objective</h3><div>This study aimed to identify key regulators of fatty acid metabolism in PH using multi-omics data and lab experiments, and to explore how they contribute to PASMC overgrowth, with the goal of uncovering new treatment targets.</div></div><div><h3>Methods</h3><div>We analyzed PH-related transcriptome data (GSE113439) and protein interaction networks to pinpoint central fatty acid metabolism genes. Functional enrichment, immune cell infiltration, and single-cell RNA sequencing (GSE210248) were used to explore the role of a key gene, ACSL4. We then screened FDA-approved drugs for potential ACSL4 inhibitors using molecular docking and dynamics simulations. Finally, in a rat model of PH induced by chronic low oxygen and in primary PASMCs, we tested how blocking ACSL4 (with the inhibitor PRGL493 or siRNA) affected cell growth and the pathways involved.</div></div><div><h3>Results</h3><div>ACSL4 stood out as a central player in fatty acid metabolism in PH. Its high expression was linked to changes in the immune environment and early disease stages. Functional analysis showed that ACSL4 and its related networks are involved in lipid metabolism, PPAR signaling, and ferroptosis. Virtual screening and molecular dynamics pointed to three FDA-approved drugs that bind tightly and steadily to ACSL4. In lab and animal studies, ACSL4 levels went up in lung tissue and PASMCs exposed to low oxygen, along with shifts in fatty acid profiles and increased PASMC growth. Blocking or silencing ACSL4 eased this overgrowth by helping restore normal VGLL4/YAP levels and reversing the suppression of the Hippo pathway.</div></div><div><h3>Conclusion</h3><div>This study uncovers a novel mechanism by which ACSL4 fuels PASMC growth in PH through reshaping fatty acid metabolism and targeting the VGLL4/YAP signaling axis. Although the role of ACSL4 in pulmonary hypertension has been previously reported, its function via the VGLL4/YAP axis is a novel finding. These findings highlight a key pathway in PH progression and point to ACSL4 as a possible target for new treatments.</div></div>","PeriodicalId":23949,"journal":{"name":"Vascular pharmacology","volume":"164 ","pages":"Article 107694"},"PeriodicalIF":3.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vascular pharmacologyPub Date : 2026-09-01Epub Date: 2026-08-15DOI: 10.1016/j.vph.2026.107689
Rosalinda Madonna, Raffaele De Caterina
{"title":"From the University of Pisa cardiovascular summer school to a multidimensional view of cardiovascular medicine","authors":"Rosalinda Madonna, Raffaele De Caterina","doi":"10.1016/j.vph.2026.107689","DOIUrl":"10.1016/j.vph.2026.107689","url":null,"abstract":"","PeriodicalId":23949,"journal":{"name":"Vascular pharmacology","volume":"164 ","pages":"Article 107689"},"PeriodicalIF":3.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vascular pharmacologyPub Date : 2026-06-01Epub Date: 2026-05-22DOI: 10.1016/j.vph.2026.107655
Dominick Openko, Michael V. Autieri
{"title":"N6-methyladenosine (m6A) post-transcriptional modification regulation of mRNA, an overlooked therapeutic opportunity to leverage mRNA processing in vascular smooth muscle cells","authors":"Dominick Openko, Michael V. Autieri","doi":"10.1016/j.vph.2026.107655","DOIUrl":"10.1016/j.vph.2026.107655","url":null,"abstract":"<div><div>In response to pathological stimuli, VSMCs modulate from a quiescent, contractile phenotype to a synthetic, non-contractile phenotype with increased migration, proliferation, and expression of matrix and pro-inflammatory cytokines. This response necessitates modification in expression of a plethora of mRNA transcripts, which often requires fine-tuning by post-translational changes in the stability of these mRNAs. N6-methyladenosine (m6A) modification can affect the fate of many mRNA transcripts in the cell, especially mRNA stability. Various m6A regulatory proteins, such as writers (methylases), erasers (demethylases), and readers (RNA binding proteins) are involved in various homeostatic processes in the cell, and can become dysregulated in disease states, contributing to vascular pathology. Recently, it has been shown that these m6A modulatory proteins can be targeted therapeutically with small molecule inhibitors to alter their expression and activity in the cell, opening up the possibility that targeting modifiers of the mRNA methylome can be leveraged as a therapeutic opportunity to treat vascular diseases. This review describes the mechanisms and explores roles of m6A modification in mRNA processing and how these changes in the VSMC transcriptome can contribute to pathogenesis and possibly treatment of vascular diseases.</div></div>","PeriodicalId":23949,"journal":{"name":"Vascular pharmacology","volume":"163 ","pages":"Article 107655"},"PeriodicalIF":3.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148006213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}